Novartis pushes past manufacturing slowdown to launch second long-acting Copaxone copy
by Carly Helfand | Feb 13, 2018 9:32am Novartis’ copy of Teva’s long-acting Copaxone will be second to market behind
Read moreCopaxone
Teva faces billions in lost sales as court tosses four long-acting Copaxone patents
by Carly Helfand | Jan 30, 2017 11:34pm It’s déjà vu for Teva Pharmaceutical in a bad, bad way.
Read moreThe Israeli pharmaceutical giant Teva must pay over $520 million following corruption charges
The Israeli pharmaceutical giant Teva must pay over $520 million following corruption charges made by the US Department of Justice
Read moreTeva bribes doctors
Two former Teva sales representatives are claiming that the company used speaker programs to disguise unlawful prescription kickbacks for multiple-sclerosis
Read more